The Galien Forum USA 2020

PANEL
4

Chair
Mikael Dolsten, MD, PhD
Chief Scientific Officer and President
Worldwide Research, Development and Medical
Pfizer Inc.

Panelists
Penny M. Heaton, MD
Chief Executive Officer
The Bill & Melinda Gates Medical Research Institute

Dean Li, MD, PhD
Senior Vice President Discovery Sciences and Translational Medicine
Merck

John Maraganore, PhD
Chief Executive Officer
Alnylam

Jeff Spaeder, MD
Global Chief Medical & Scientific Officer
IQVIA

George Scangos, PhD
Chief Executive Officer
Vir Biotechnology

Prof. Mads Krogsgaard Thomsen, DVM, PhD, DSc
Executive Vice President and Chief Scientific Officer
Novo Nordisk A/S

Panel Intro

The Future of Therapeutics: What Novel Modalities Will Be Drugs? What Vaccines and Technologies Will We Need?


Mikael_Dolsten_Pfizer_Chair_P4 Chair
Mikael Dolsten, MD, PhD
Chief Scientific Officer and President
Worldwide Research, Development and Medical

Pfizer Inc.

Mikael leads the Worldwide Research, Development and Medical (WRDM) organization at Pfizer, which is responsible for the development of all compounds through proof of concept, and provides pharmaceutical sciences, safety and medical support to the entire R&D pipeline and all marketed products. The WRDM group contains all Pfizer research units, including Oncology, Internal Medicine, Inflammation & Immunology, Vaccines and Rare Disease, as well as the Centers for Therapeutic Innovation (CTI). Mikael has worldwide responsibility for Pfizer’s groups in medical, safety and external R&D innovation, in addition to science-based teams in pharmaceutical sciences, drug safety R&D, and large and small molecule discovery and development. Mikael is a member of the Executive Leadership Team and Pfizer’s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities.

Mikael earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden and was appointed Adjunct Professor in Tumor Immunology. He is a governor of the New York Academy of Sciences and serves on the PhRMA Research & Development Leadership Forum, the PhRMA Foundation Board of Directors, and the Board of Karyopharm Therapeutics. Mikael is a member of the Board of Overseers – Scripps Research Institute as well as a Foreign Member of The Royal Swedish Academy of Engineering Sciences. Since 2014, Mikael has co-chaired the Accelerating Medicine Partnership (AMP) with National Institutes of Health (NIH) Director Francis S. Collins. Mikael advised the Obama Administration on R&D as well as Vice President Biden’s Cancer Moonshot Initiative to accelerate cancer research.

Mikael is a named inventor on several patents and has published approximately 150 articles in international journals.


Penny_Heaton_B&M_Gates_Foundation_P4Penny M. Heaton, MD
Chief Executive Officer
The Bill & Melinda Gates Medical Research Institute

Dr. Penny M. Heaton is the Chief Executive Officer of the Bill & Melinda Gates Medical Research Institute (Gates MRI), a non-profit biotechnology organization that applies translational science to combat diseases that disproportionately impact the poor in low- and middle-income countries.

Dr. Heaton leads the institute’s work to capitalize on new strategies and partnerships to optimize therapeutics, vaccines and monoclonal antibody candidates, accelerate progress from the lab to the clinic and develop them through proof of concept in target populations. The mission of the Gates MRI is to advance or develop products that will help eradicate malaria, accelerate the end of the tuberculosis epidemic, prevent diarrheal deaths from occurring in children and improve maternal and neonatal health outcomes.

Prior to this role, Dr. Heaton served as Director of the Bill & Melinda Gates Foundation’s Vaccine Development and Surveillance team, which provided strategic and technical support to the foundation’s vaccine development programs against several diseases including HIV, TB, malaria, pneumonia, enteric diseases, and polio. She has more than 20 years of experience leading vaccine clinical research and development for companies including Novartis, Merck and Novavax.

Dr. Heaton began her career at the U.S. Centers for Disease Control and Prevention conducting diarrheal disease surveillance and investigating outbreaks of foodborne and diarrheal diseases, influencing her life-long passion for vaccine development. Notably, Dr. Heaton co-developed RotaTeq® during her time at Merck & Co., Inc., a rotavirus vaccine which has been licensed in more than 100 countries and universally recommended by the World Health Organization for infants worldwide.

A graduate of the University of Louisville School of Medicine in Kentucky, Dr. Heaton is board-certified in Pediatrics and Pediatric Infectious Diseases. She is a member of the Pediatric Infectious Diseases Society and a fellow of the American Academy of Pediatrics.


Dean_Li_P4Dean Li, MD, PhD
Senior Vice President Discovery Sciences and Translational Medicine
Merck

Dean Li, MD, PhD is Senior Vice President Discovery Sciences and Translational Medicine at Merck. Prior to joining Merck in March of 2017, Dean previously served as the Chief Scientific Officer, Associate Vice President and Vice Dean at the University of Utah Health System, and CEO of ARUP Laboratories, a major national reference laboratory wholly owned by the University of Utah. His academic laboratory utilized human genetics as an entry point to explore signaling pathways critical for vascular biology, cancer and inflammation. Findings from his academic investigations help to nucleate three biotechnology companies (Hydra Biosciences, Navigen Pharmaceuticals, Recursion Pharmaceuticals). Dean served as the founding CSO for each of these companies. Dean is a board-certified cardiologist and a member of the American Society of Clinical Investigation and the Association of American Physicians. Dean received his undergraduate degree in Chemistry from the University of Chicago and his graduate and clinical training at Washington University School of Medicine in St. Louis.


John_Maraganore_Alnylam_P4John Maraganore, PhD
Chief Executive Officer
Alnylam

Since 2002, Dr. John Maraganore has served as the CEO and a Director of Alnylam.
Prior to Alnylam, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company’s product franchises in oncology, and cardiovascular, inflammatory, and metabolic diseases. He was previously Vice President, Strategic Planning and M&A and, prior to that, he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, formerly HIRULOGTM and currently marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and the Upjohn Company.

Dr. Maraganore received his Master of Science and Ph.D. in biochemistry and molecular biology at the University of Chicago. He is a member of the Board for Agios Pharmaceuticals and Biotechnology Industry Organization (BIO) Board and is a member of the BIO Executive Committee.


Jeffrey_Spaeder_IQVIA_P4Jeff Spaeder, MD
Global Chief Medical & Scientific Officer
IQVIA

Jeffrey Spaeder, M.D. is Chief Medical and Scientific Officer for IQVIA. In this role, he is the lead medical and scientific expert and is involved with the company’s oversight of scientific integrity, governance of early phase development, quality assurance, and bioethics.

Jeff has over 25 years of medical and research experience, and since 2005 has worked in the life sciences industry. Prior to joining IQVIA, Jeff worked in roles of increasing responsibility at Abbott Laboratories and Takeda in clinical development, pharmacovigilance, and medical affairs. He also was a cardiologist on the faculty of Johns Hopkins School of Medicine, where he performed novel research on mass customization of personalized healthcare and telemedicine, and he holds several patents based on his research and insights.

Jeff holds an M.D. degree from Johns Hopkins School of Medicine and completed specialty training in internal medicine at Johns Hopkins and sub-specialty training in cardiovascular medicine from Johns Hopkins and the National Heart, Lung, and Blood Institute. He holds an undergraduate degree (B.S.) in Engineering Science from The Pennsylvania State University and a Master’s in Business Administration (M.B.A.) with a concentration in Finance from Northwestern University’s Kellogg School of Management.


George_Scangos_Vir_P4George Scangos, PhD
Chief Executive Officer
Vir Biotechnology

George Scangos, Ph.D., has served as Vir’s President and Chief Executive Officer and as a member of Vir’s board of directors since January 2017. From July 2010 to December 2016, Dr. Scangos served as Chief Executive Officer and as a member of the board of directors of Biogen Inc., a publicly traded biopharmaceutical company focused on the treatment of serious diseases. From October 1996 to July 2010, Dr. Scangos served as President and Chief Executive Officer at Exelixis, Inc., a drug discovery and development company. From 1993 to 1996, Dr. Scangos served as President of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer Biotechnology’s biological products. Before joining Bayer Biotechnology in 1987, Dr. Scangos was a Professor of Biology at Johns Hopkins University.
Dr. Scangos received his B.A. in Biology from Cornell University and a Ph.D. in Microbiology from the University of Massachusetts.


Mads_Krogsgaard_Thomsen_Novo_Nordisk_Forum_P4Prof. Mads Krogsgaard Thomsen, DVM, PhD, DSc
Executive Vice President and Chief Scientific Officer
Novo Nordisk A/S

Mads Krogsgaard Thomsen is a Danish native born in 1960 and receiving his school education in United Kingdom and Denmark. In 1986, professor Thomsen graduated from Copenhagen University where he later also obtained his PhD and DSc degrees within the pharmacology of experimental therapeutics. After three years of pharmacological research at Leo Pharma, he joined Novo Nordisk A/S where he was head of Growth Hormone research, Diabetes R&D, Global Drug Discovery and, since 2000, Executive Vice President and Chief Science Officer. In this role, he is responsible for global drug and device research, CMC and global development, medical affairs, regulatory and safety within Novo Nordisk.
Professor Thomsen has chaired Danish Research Council programmes within endocrinology and served as President of the Danish Academy of Technical Sciences. Professor Thomsen has been board member of the Danish Technical University, Cellartis AB, Steno Diabetes Center, Symphogen A/S and Chairman of the Board of the University of Copenhagen, Denmark. Today, he serves as member of the board of BB Biotech, Switzerland.

Professor Thomsen is also a member of the editorial boards of international, peer-reviewed journals. Since 2000, he has served as adjunct Professor of pharmacology at the Life Sciences faculty of Copenhagen University.

At a national level, Professor Thomsen has acted as Chairman of the Danish Biotech, Research and Innovation Centre during its establishment, as well as on governmental committees, e.g. related to revision of the Danish system for post-graduate studies. His scientific publications include books, chapters and scientific papers within pharmacology, immunology, endocrinology and haemostasis.